Ignite Creation Date:
2024-05-06 @ 3:26 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04630769
Status:
COMPLETED
Last Update Posted:
2023-04-03
First Post:
2020-11-11
Brief Title:
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Sponsor:
Masonic Cancer Center University of Minnesota
Organization:
Masonic Cancer Center University of Minnesota
Organization Data
Organization:
Masonic Cancer Center University of Minnesota
Class:
OTHER
Study ID:
2020LS001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Masonic Cancer Center University of Minnesota
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |